STEMCELL-TECHNOLOGIES
STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit has been granted de novo classification by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240326396951/en/
STEMCELL Technologies is pleased to announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit is now classified by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment. (Photo: Business Wire)
The kit can be used to enrich plasma cells expressing the CD138 marker (CD138+ cells) from patient bone marrow samples. Such cell-type-specific enrichment can increase the sensitivity of downstream in vitro diagnostic tests for multiple myeloma—a cancer of plasma cells—to better inform patient risk and course of treatment. Accounting for approximately 2% of all cancers in the United States1, multiple myeloma is incurable, and variable or low frequencies of CD138+ cells in bone marrow samples can impact the reliability of detecting genetic abnormalities that influence the disease’s progression. Incorporation of STEMCELL's new kit in a pre-analytical step of the diagnostic workflow can contribute to improving patient care and outcomes by enhancing the sensitivity and resolution of these downstream assays.
“STEMCELL is proud to develop the first hematopoietic cell enrichment product identified as an in vitro diagnostic device by the FDA,” said Dr. Allen Eaves, President and CEO, STEMCELL. “Creating an IVD product that improves the accuracy of information guiding the treatment of patients with multiple myeloma is a milestone achievement that reflects our commitment to make a positive impact on human health.”
The FDA identifies this new product type as a hematopoietic cell enrichment kit: a Class II IVD device for selecting specific cells from human whole blood or bone marrow, intended for use with diagnostic assays as part of the pre-analytical workflow. Agencies such as the National Comprehensive Cancer Network and the American College of Medical Genetics recommend CD138+ cell enrichment upstream of fluorescence in situ hybridization (FISH) testing for multiple myeloma; however, until now, hematopoietic cell enrichment products have not been classified as IVD devices by the FDA.
“This De Novo classification will have a permanent impact on the IVD landscape and paves the way for further innovation,” said Dr. Eaves. “STEMCELL is committed to building on this foundational work in the IVD field with novel diagnostic products and support, including supporting industry partnerships through our Diagnostics Partnerships and OEM Solutions Program.”
The EasySep™ Human Bone Marrow CD138 Positive Selection Kit is part of STEMCELL’s portfolio of EasySep™ immunomagnetic cell isolation technologies, specifically developed for fast and easy isolation of highly purified cells that are ready for downstream applications. It marks the culmination of many years of work, which included examining more than 230 bone marrow aspirates from multiple myeloma patients, precision studies of inter- and intra-laboratory reproducibility, and limit of detection and interference studies. The EasySep™ Human Bone Marrow CD138 Positive Selection Kit will be available for sale in the United States, the European Union, Canada, and the United Kingdom.
1Padala et al. 2021 Med Sci (Basel)
About STEMCELL Technologies
STEMCELL Technologies supports life sciences research with more than 2,500 specialized reagents, tools, and services. STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326396951/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ViTAA Medical Secures FDA 510(k) Clearance for AiORTA™ Plan — Marking the First Step in Its Hyper-Precise Aortic Care Platform12.11.2025 16:00:00 CET | Press release
FDA clearance marks a pivotal milestone in ViTAA’s broader AiORTA™ suite, designed to support physicians across the full continuum of aortic care ViTAA Medical Solutions Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for AiORTA™ Plan, the company’s fully automated, hyper-precise aortic surgery planning solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112394413/en/ This clearance represents a key milestone in the evolution of ViTAA’s broader AiORTA™ platform, built to support physicians across the full continuum of aortic care. ViTAA’s additional innovations—AiORTA™ Maps and AiORTA™ Watch—are currently in multicenter clinical studies, progressing rapidly toward future clinical release. A Leap Forward in Aortic Surgery Planning Built to automate key preoperative measurements and streamline aortic case prep, AiORTA™ Plan generates a complete aortic plan in minutes.
Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 202512.11.2025 15:30:00 CET | Press release
– Multiple presentations on vimseltinib for the treatment of Tenosynovial Giant Cell Tumor (TGCT), including encore data from the Phase 3 MOTION study presented in an oral session – – Two posters on DCC-3009 in Gastrointestinal Stromal Tumor (GIST) – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that data from multiple pipeline programs, including long-term and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option, will be presented during the CTOS Annual Meeting 2025, taking place November 12-15 in Boca Raton, Florida. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112742665/en/ “We are excited about the breadth of data we’re presenting at CTOS this year, which underscore the strong progress we continue to sustain across our pipeline,” said Matthew L. Sherman, M.D
Deskpro Launches New Private Help Desk Solution with Private AI Support for Organizations with Strict Security, Compliance, and Data Sovereignty Requirements12.11.2025 15:13:00 CET | Press release
Deskpro Private Eliminates Impossible Choice Between AI Capabilities and Data Security for Organizations Including Financial Services, Healthcare, Aerospace and Defense, and Government Today, Deskpro, provider of the secure AI-powered help desk platform, announced the launch of Deskpro Private, making AI-powered help desk capabilities available to industries with stringent security and compliance requirements for the first time. The new platform delivers flexible private deployment, allowing companies to run their AI-powered help desk entirely within their AWS Virtual Private Cloud (VPC), on-premise enterprise data center, or sovereign cloud. Enterprises can connect to their AI of choice, including commercial, public, private, custom, and open source models, using existing organizational accounts and APIs. This means sensitive data never leaves the organization’s approved security perimeter. With Deskpro, organizations no longer need to sacrifice the measurable ROI from AI capabilities
New Study Reveals Tech Industry Leads AI Adoption in Support Operations at 92%; Regulated Industries Only at 58% Due to Compliance Constraints12.11.2025 15:06:00 CET | Press release
Research Finds Security and Compliance Requirements Are Reshaping Technology Adoption, with Healthcare, Finance, and Government Organizations Facing Deployment Constraints that Technology Companies Avoid Today, Deskpro, provider of the secure AI-powered help desk platform, released results from the State of AI in Support Operations: Balancing Innovation and Compliance report, which quantifies how security and compliance requirements are creating distinct market segments with vastly different AI adoption rates. According to the data, 92% of technology companies are adopting AI for support operations, while companies in regulated industries are significantly lagging behind with a 58% adoption rate. This 34-point gap reflects a significant disconnect: organizations are eager to adopt AI-powered support solutions, but face significant barriers related to data security, compliance and regulatory requirements, and deployment flexibility. While market demand for AI support capabilities exists
Ran Kurup Joins MinIO to Accelerate Corporate Strategic Growth12.11.2025 15:00:00 CET | Press release
MinIO, the data foundation for Enterprise AI, today announced the appointment of Ran Kurup as Chief Corporate Development Officer. In this newly created role, Kurup will lead MinIO’s global strategic growth initiatives, including geographic expansion, mergers and acquisitions, and other investment strategies designed to extend the company’s leadership in enterprise AI data infrastructure. Kurup joins MinIO from Intel Capital, where he played a central role in supporting high-growth companies across AI, data infrastructure, and enterprise technology. His extensive experience in driving operational scale for a wide range and quantity of investments positions him to advance MinIO’s long-term growth objectives. “Ran’s appointment underscores MinIO’s commitment to executing a disciplined and expansive growth strategy,” said Garima Kapoor, Co-founder and Co-CEO of MinIO. “As we continue to scale globally, his experience at the intersection of technology investment and enterprise transformati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom